Arbutus Biopharma (ABUS) Share-based Compensation (2013 - 2026)

Arbutus Biopharma has disclosed Share-based Compensation across 14 years of filings, most recently posting $1.4 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $1.4 million, down 61.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.7 million (down 54.94% YoY), and the FY2025 annual result was $7.0 million, down 22.62% from the prior year.
• Share-based Compensation came in at $1.4 million for Q1 2026 at Arbutus Biopharma, up from $1.3 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $3.6 million in Q1 2025 to a low of $864000.0 in Q2 2025.
• The 5-year median for Share-based Compensation is $1.7 million (2022), against an average of $2.0 million.
• Peak annual rise in Share-based Compensation reached 76.96% in 2025, while the deepest fall reached 72.83% in 2025.
• Arbutus Biopharma's Share-based Compensation stood at $1.7 million in 2022, then increased by 3.36% to $1.7 million in 2023, then fell by 5.28% to $1.6 million in 2024, then decreased by 22.67% to $1.3 million in 2025, then advanced by 7.69% to $1.4 million in 2026.
• The last three Share-based Compensation figures came in at $1.4 million (Q1 2026), $1.3 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.